Evidence map›Paper›PMID 40216647›Full record

ArticleMedical oncology (Northwood, London, England)2025

The role of FOXA1 and miR-212-3p in molecular modulation of doxorubicin resistance in liver cancer.

Ammar Elfiky, Nadia El-Guendy, Abeer Mahmoud Badr, Mohammed Aly Mohammed, Abdel Hady A Abdel Wahab

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ammar ElfikyMedical Biochemistry and Molecular Biology at Cancer Biology Department National Cancer Institute, Cairo University, Giza, Egypt.
Nadia El-GuendyMedical Biochemistry and Molecular Biology at Cancer Biology Department National Cancer Institute, Cairo University, Giza, Egypt.
Abeer Mahmoud BadrZoology Department, Faculty of Science, Cairo University, Giza, 12613, Egypt.
Mohammed Aly MohammedMedical Biochemistry and Molecular Biology at Cancer Biology Department National Cancer Institute, Cairo University, Giza, Egypt.
Abdel Hady A Abdel WahabMedical Biochemistry and Molecular Biology at Cancer Biology Department National Cancer Institute, Cairo University, Giza, Egypt. abdelhady.abdelwahab@nci.cu.edu.eg.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

TACE (Transarterial Chemoembolization) is an essential current treatment for liver cancer. Resistance to doxorubicin, the chemotherapeutic component of TACE, poses a serious problem in this treatment, necessitating a deeper understanding of the underlying resistance mechanisms. Upregulation of the Forkhead box A1 transcription regulator in our model of doxorubicin-resistant liver cancer cell line suggested a role in resistance. To better understand the role of FOXA1 in resistance to doxorubicin, we inhibited its expression using siRNA or its miRNA-212-3p inhibitor then studied the effect on the cancer cell lines survival using SRB assay. The expression of several downstream epithelial-mesenchymal transition genes, namely SLUG, TWIST, CDH1 (E-Cadherin), was determined using quantitative real-time PCR. Our results showed a significant upregulation of FOXA1 and downregulation of miRNA-212-3p in doxorubicin-resistant cells. Manipulation of FOXA1 and miRNA-212-3p expressions restored sensitive cell characteristics. In addition, inhibition of FOXA1 increased apoptosis induction in resistant cells. Changes detected in the tested EMT genes point to progression toward more aggressive behavior in the doxorubicin-resistant liver cancer cell line that was reversed with inhibition of FOXA1. Our results suggest a possible role of FOXA1 and miRNA-212-3p in the development of resistance to chemotherapeutic drugs in liver cancer and the possibility of their use as prognostic and/or therapeutic targets.

Indexed as

Antibiotics, AntineoplasticCarcinoma, HepatocellularDoxorubicinDrug Resistance, NeoplasmHepatocyte Nuclear Factor 3-alphaLiver NeoplasmsMicroRNAsApoptosisCell Line, TumorEpithelial-Mesenchymal TransitionGene Expression Regulation, NeoplasticHumansAntibiotics, AntineoplasticDoxorubicinFOXA1 protein, humanHepatocyte Nuclear Factor 3-alphaMicroRNAsMIRN212 microRNA, humanDoxorubicinDrug resistanceFOXA1Liver cancerMicroRNA

Identifiers

PMID40216647
PMCPMC11991990

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.